Department of Microbial Chemistry, Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Medicinal Research Laboratories, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
J Antibiot (Tokyo). 2020 Aug;73(8):581-584. doi: 10.1038/s41429-020-0290-9. Epub 2020 Mar 4.
The marine actinomycete strain OPMA02852, identified as the genus Streptomyces, was found to produce anti-mycobacterial compounds against Mycobacterium avium complex (MAC). One new compound, designated as steffimycin E (1), was isolated together with three known steffimycins (steffimycin (2), 10-dihydrosteffimycin (3), and 8-demethoxysteffimycin (4)) from the culture broth of this producing microorganism by solvent extraction, ODS column chromatography, and preparative HPLC. Compound 1 has a tetracyclic quinone structure with a sugar moiety. Compound 1 exhibited anti-mycobacterial activity against M. intracellulare, M. bovis BCG, and M. smegmatis.
海洋放线菌 OPMA02852 菌株被鉴定为链霉菌属，能够产生抗分枝杆菌化合物来抑制鸟分枝杆菌复合群（MAC）。从该产生菌的发酵液中，通过溶剂萃取、ODS 柱层析和制备型 HPLC，分离得到一个新化合物，命名为 steffimycin E（1），以及三个已知化合物 steffimycin（2）、10-二氢 steffimycin（3）和 8-去甲氧基 steffimycin（4）。化合物 1 具有四环醌结构和糖部分。化合物 1 对胞内分枝杆菌、牛分枝杆菌 BCG 和耻垢分枝杆菌表现出抗分枝杆菌活性。
